Daiichi Sankyo and AstraZeneca announced that Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in China for the first-line treatment of adult patients with unresectable or… read more.
10 August 2026 – Kura Oncology, Inc. announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and… read more.
4 August 2026 – GE HealthCare announced the introduction of the Logiq e family, featuring Logiq e Xi and Logiq e Si, two compact laptop ultrasound systems designed… read more.
Abbott announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott’s Lingo biowearable with Google’s expertise… read more.
Idorsia Ltd announces that the US Drug Enforcement Administration (DEA) will publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V… read more.
NICE: Finerenone can be used, within its marketing authorisation, as an option to treat symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. Why… read more.
Bavarian Nordic A/S announced that the European Commission has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type… read more.
7 August 2026 – Astellas Pharma Inc. confirms it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking approval of… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron (Foundayo), making the UK the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased… read more.
Outlook Therapeutics, Inc. announced that the FDA has approved Lytenava (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The approval establishes… read more.
According to the Medicines and Healthcare products Regulatory Agency (MHRA) website, an intravesical delivery system containing gemcitabine (Inqlexzo) has been authorised for the treatment of adults for certain… read more.
Moderna, Inc. announced that the FDA has approved Mflusiva (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
